Wuxi Biologics 2269

Wuxi Biologics 2269

Postby winston » Thu Oct 22, 2020 3:25 pm

not vested

Wuxi Biologics (2269 HK) - Guidance raised

Wuxi Biologics is a leading global open-access biologics technology platform offering end-to-end solutions services to support global corporate clients in the development process of discovery, development and manufacturing of biologics.

The company is the first Chinese biologics company approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and operates multiple world class Good Manufacturing Practices (GMP) manufacturing facilities for biologics production.

Its estimated market shares are ~78.6% (China) and ~5.1% globally (behind global peers such as Lonza and IQVIA).

Key strengths include its multiple leading platforms, expertise to conduct clinical trials, solid execution and track record, and lower labour costs which have helped in project wins and customer stickiness.

Despite the pandemic impact on the business in 1H20, 2020 should still close with meaningful growth supported by new Covid-19 related projects the company clinched due to its quick response time and premier technology platforms.

Being in a growth phase with meaningful expansion plans, the company does not pay dividends. BUY.

Source: OCBC
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
Billionaire Boss
Posts: 109462
Joined: Wed May 07, 2008 9:28 am

Return to S to Z

Who is online

Users browsing this forum: No registered users and 1 guest